Diaz LA Jr et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2022;23(5):659-70. Abstract
Doleschal B et al. Current concepts of anti-EGFR targeting in metastatic colorectal cancer. Front Oncol 2022;12:1048166. Abstract
Eng C et al. A comprehensive framework for early-onset colorectal cancer research. Lancet Oncol 2022;23(3):e116-28. Abstract
Holowatyj AN et al. Gut instinct: A call to study the biology of early-onset colorectal cancer disparities. Nat Rev Cancer 2021;21(6):339-40. Abstract
Kotani D et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med 2023;29(1):127-34. Abstract
Lieu C. The use of immunotherapy in metastatic microsatellite-stable colorectal cancer. Clin Adv Hematol Oncol 2022;20(12):703-4. Abstract
Paez D et al. Trial in progress: A phase III global study of sotorasib, a specific KRAS G12C inhibitor, in combination with panitumumab versus investigator’s choice in chemorefractory metastatic colorectal cancer (CodeBreaK 300). ESMO 2022;Abstract 437TiP.
Pfeiffer P et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: An investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21(3):412-20. Abstract
Sahin IH et al. Minimal residual disease-directed adjuvant therapy for patients with early-stage colon cancer: CIRCULATE-US. Oncology (Williston Park) 2022;36(10):604-8. Abstract
Strickler JH et al. Additional analyses of MOUNTIANEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC. ESMO 2022;Abstract LBA27.
Strickler JH et al. Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC. ESMO 2022;Abstract LBA2.
Tabernero J et al. BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC). ESMO 2022;Abstract LBA26.
Tabernero J et al. Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study. Gastrointestinal Cancers Symposium 2023;Abstract 4.
Tie J et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022;386(24):2261-72. Abstract
Yaeger R et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med 2022;388(1):44-54. Abstract
Yoshino T et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. ASCO 2022;Abstract LBA1.
Yoshino T et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). Gastrointestinal Cancers Symposium 2022;Abstract 119.